logo

Pulmatrix Inc. (PULM)



Trade PULM now with
  Date
  Headline
8/10/2021 9:13:43 AM Pulmatrix Q2 Net Loss $3.9 Mln Vs Loss Of $1.2 Mln Last Year
4/12/2021 9:16:09 AM Pulmatrix To Regain Full Rights To Its Narrow Spectrum Kinase Inhibitor Portfolio
2/11/2021 12:33:24 AM Pulmatrix Announces $40 Mln Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
10/21/2020 9:09:08 AM Pulmatrix Announces Marketing And Distribution Partner Sensory Cloud's Commercial Launch Of FEND
9/30/2020 9:22:29 AM Pulmatrix Announces Publication Demonstrating Reduction Of Bioaerosols With FEND
9/29/2020 8:33:54 AM Pulmatrix Appoints Todd Bazemore To Board, Effective October 1, 2020
5/14/2020 9:07:22 AM Pulmatrix Q1 Net Loss $4.7 Mln Vs. Loss $5.2 Mln Prior Year
3/26/2020 9:05:17 AM Pulmatrix 2019 Revenue Rises To $7.9 Mln From $0.2 Mln Prior Year
1/30/2020 8:13:13 AM Pulmatrix: FDA Grants Fast Track Designation For Pulmazole For The Treatment Of Asthma-ABPA
1/16/2020 12:30:05 PM Pulmatrix Regains Compliance With Nasdaq Minimum Bid Price Requirement
1/2/2020 8:52:30 AM Pulmatrix Enters Licensing And Development Agreement With The Lung Cancer Initiative At Johnson & Johnson